Cargando…

Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora

Liver cirrhosis is a form of liver fibrosis resulting from chronic hepatitis caused by various liver diseases, such as viral hepatitis, alcoholic liver damage, nonalcoholic steatohepatitis, autoimmune liver disease, and by parasitic diseases such as schistosomiasis. Liver fibrosis is the common path...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xianzhi, Wang, Lifu, Tan, Siwei, Chen, Zebin, Wu, Bin, Wu, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924518/
https://www.ncbi.nlm.nih.gov/pubmed/35308208
http://dx.doi.org/10.3389/fphar.2022.814871
_version_ 1784669874666078208
author Liu, Xianzhi
Wang, Lifu
Tan, Siwei
Chen, Zebin
Wu, Bin
Wu, Xiaoying
author_facet Liu, Xianzhi
Wang, Lifu
Tan, Siwei
Chen, Zebin
Wu, Bin
Wu, Xiaoying
author_sort Liu, Xianzhi
collection PubMed
description Liver cirrhosis is a form of liver fibrosis resulting from chronic hepatitis caused by various liver diseases, such as viral hepatitis, alcoholic liver damage, nonalcoholic steatohepatitis, autoimmune liver disease, and by parasitic diseases such as schistosomiasis. Liver fibrosis is the common pathological base and precursors of cirrhosis. Inflammation and disorders of lipid metabolism are key drivers in liver fibrosis. Studies have determined that parts of the arachidonic acid pathway, such as its metabolic enzymes and biologically active products, are hallmarks of inflammation, and that aberrant peroxisome proliferator-activated receptor gamma (PPARγ)-mediated regulation causes disorders of lipid metabolism. However, despite the ongoing research focus on delineating the mechanisms of liver fibrosis that underpin various chronic liver diseases, effective clinical treatments have yet to be developed. Berberine (BBR) is an isoquinoline alkaloid with multiple biological activities, such as anti-inflammatory, anti-bacterial, anti-cancer, and anti-hyperlipidemic activities. Many studies have also found that BBR acts via multiple pathways to alleviate liver fibrosis. Furthermore, the absorption of BBR is increased by nitroreductase-containing intestinal flora, and is strengthened via crosstalk with bile acid metabolism. This improves the oral bioavailability of BBR, thereby enhancing its clinical utility. The production of butyrate by intestinal anaerobic bacteria is dramatically increased by BBR, thereby amplifying butyrate-mediated alleviation of liver fibrosis. In this review, we discuss the effects of BBR on liver fibrosis and lipid metabolism, particularly the metabolism of arachidonic acid, and highlight the potential mechanisms by which BBR relieves liver fibrosis through lipid metabolism related and intestinal flora related pathways. We hope that this review will provide insights on the BBR-based treatment of liver cirrhosis and related research in this area, and we encourage further studies that increase the ability of BBR to enhance liver health.
format Online
Article
Text
id pubmed-8924518
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89245182022-03-17 Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora Liu, Xianzhi Wang, Lifu Tan, Siwei Chen, Zebin Wu, Bin Wu, Xiaoying Front Pharmacol Pharmacology Liver cirrhosis is a form of liver fibrosis resulting from chronic hepatitis caused by various liver diseases, such as viral hepatitis, alcoholic liver damage, nonalcoholic steatohepatitis, autoimmune liver disease, and by parasitic diseases such as schistosomiasis. Liver fibrosis is the common pathological base and precursors of cirrhosis. Inflammation and disorders of lipid metabolism are key drivers in liver fibrosis. Studies have determined that parts of the arachidonic acid pathway, such as its metabolic enzymes and biologically active products, are hallmarks of inflammation, and that aberrant peroxisome proliferator-activated receptor gamma (PPARγ)-mediated regulation causes disorders of lipid metabolism. However, despite the ongoing research focus on delineating the mechanisms of liver fibrosis that underpin various chronic liver diseases, effective clinical treatments have yet to be developed. Berberine (BBR) is an isoquinoline alkaloid with multiple biological activities, such as anti-inflammatory, anti-bacterial, anti-cancer, and anti-hyperlipidemic activities. Many studies have also found that BBR acts via multiple pathways to alleviate liver fibrosis. Furthermore, the absorption of BBR is increased by nitroreductase-containing intestinal flora, and is strengthened via crosstalk with bile acid metabolism. This improves the oral bioavailability of BBR, thereby enhancing its clinical utility. The production of butyrate by intestinal anaerobic bacteria is dramatically increased by BBR, thereby amplifying butyrate-mediated alleviation of liver fibrosis. In this review, we discuss the effects of BBR on liver fibrosis and lipid metabolism, particularly the metabolism of arachidonic acid, and highlight the potential mechanisms by which BBR relieves liver fibrosis through lipid metabolism related and intestinal flora related pathways. We hope that this review will provide insights on the BBR-based treatment of liver cirrhosis and related research in this area, and we encourage further studies that increase the ability of BBR to enhance liver health. Frontiers Media S.A. 2022-03-02 /pmc/articles/PMC8924518/ /pubmed/35308208 http://dx.doi.org/10.3389/fphar.2022.814871 Text en Copyright © 2022 Liu, Wang, Tan, Chen, Wu and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Xianzhi
Wang, Lifu
Tan, Siwei
Chen, Zebin
Wu, Bin
Wu, Xiaoying
Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
title Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
title_full Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
title_fullStr Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
title_full_unstemmed Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
title_short Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora
title_sort therapeutic effects of berberine on liver fibrosis are associated with lipid metabolism and intestinal flora
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924518/
https://www.ncbi.nlm.nih.gov/pubmed/35308208
http://dx.doi.org/10.3389/fphar.2022.814871
work_keys_str_mv AT liuxianzhi therapeuticeffectsofberberineonliverfibrosisareassociatedwithlipidmetabolismandintestinalflora
AT wanglifu therapeuticeffectsofberberineonliverfibrosisareassociatedwithlipidmetabolismandintestinalflora
AT tansiwei therapeuticeffectsofberberineonliverfibrosisareassociatedwithlipidmetabolismandintestinalflora
AT chenzebin therapeuticeffectsofberberineonliverfibrosisareassociatedwithlipidmetabolismandintestinalflora
AT wubin therapeuticeffectsofberberineonliverfibrosisareassociatedwithlipidmetabolismandintestinalflora
AT wuxiaoying therapeuticeffectsofberberineonliverfibrosisareassociatedwithlipidmetabolismandintestinalflora